Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.
Clinical trial NCT06581562 · RECRUITING
Trial details
- NCT number
- NCT06581562
- Sponsor
- IRIS Research and Development, LLC
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2024-05-15
- Primary completion
- 2027-07-01
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.